Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

On The Pen: The Weekly Dose 7.2.24

On The Pen: The Weekly Dose 7.2.24

FromOn The Pen: The Weekly Dose


On The Pen: The Weekly Dose 7.2.24

FromOn The Pen: The Weekly Dose

ratings:
Length:
20 minutes
Released:
Jul 2, 2024
Format:
Podcast episode

Description

Send us a Text Message.Get OTP Emails: https://www.onthepen.com/emailsEli LillyEli Lilly sent cease and desist letters to providers of research grade GLP-1sExclusive news from onthepen.com that has not been covered by any other sourcehttps://www.onthepen.com/post/generic-versions-of-zepbound-how-recent-news-affects-their-futureHim & Hers:Him & Hers giving GLP medications without consulting with a doctorhttps://hntrbrk.com/hims/Price for generic liraglutide/Victoza (multiple tiktok videos):Note: podcast last week announced generic liraglutide from Tera PharmaPrices as low as $225 for two penshttps://www.goodrx.com/liraglutide?form=carton&dosage=2-pens-of-18mg-3ml&quantity=1&label_override=liraglutideTROAScaled-back TROA bill is passed out of the US House Ways and Means Committee This version would limit coverage to people who had been taking a weight loss drug for a year prior to enrolling in Medicarehttps://www.nbcnews.com/health/health-news/house-committee-passes-bill-allow-medicare-cover-weight-loss-drugs-rcna159248BI 3034701 (tiktok video):Boehringer Ingelheim and Gubra start phase 1 trial of BI 3034701 which is retatrutide competitor (GLP-1/GIP/glucagon)https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/phase-1-start-novel-triple-agonist-obesity-treatmentSupport the Show.MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:Venmo: OnThePenCa$h App: ManOnMounjaroBECOME A MEMBER:https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/joinSOCIAL LINKShttps://www.tiktok.com/@manonthemounjarohttps://twitter.com/ManOnMounjarohttps://instagram.com/manonthemounjarohttps://facebook.com/manonthemounjaro? Contact Me: MounjaroMan@gmail.com? PLAYLISTS:?️ ON THE PEN LIVES:https://www.youtube.com/playlist?list=PLtOcNl0C8quVdrWruYSrJpTZPF7jjXKfM? WATCH MY MOUNJARO JOURNEY IN ORDER:https://www.youtube.com/watch?v=aplFxNOv77g&list=PLtOcNl0C8quWo7PWY9j_HilhWIRuedyiO? NERDS ONLY: LEARN ABOUT OTHER GLP-1 MEDS:https://www.youtube.com/playlist?list=PLtOcNl0C8quW-YZuu_DSpt_NS9fVQbMoW?? ALL THE LATEST MOUNJARO NEWS:https://www.youtube.com/playlist?list=PLtOcNl0C8quVo0I2YODK-q7cHh4y1r2yBThank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com.
Released:
Jul 2, 2024
Format:
Podcast episode

Titles in the series (36)

Get your weekly dose of everything in the news about incretin mimetic therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!